Five "2020" new pharmaceutical companies, sales cost rate of more than 30% in 2019

[
pharmacy network market analysis] has been selling expenses A-share pharmaceutical companies criticized the high marketAccording to Wind data show that as of May 17, A shares of the pharmaceutical sector stocks a total of 328 stocks, 118 stocks cost of sales rate of over 30% in 2019, accounting for the number of pharmaceutical stocks ratio of about 35.98%It is noteworthy that, in this 118 pharmaceutical companies, there are five to "2020" new, including Guizhou Sanli, three friends of the medical, New South pharmaceutical, Bio Integration, special biological treasureGuizhou Sanlionly the first half of 2019, cost of sales amounted to three of the pharmacy 153 million yuan, accounting for 43.88% the proportion of current operating income, sales higher costsThree of the pharmacy has said in the prospectus, the company higher marketing costs ratio was mainly due to the company specialized academic promotion sales model dueAnd, under the specialized academic promotion model, the company through the conference and exhibition, doctors visits, customer care, marketing promotion information gathering, etc., so the higher marketing expenses accounted forpublic information, Guizhou Sanli Ltd, a pharmaceutical research and development, production and salesThe main product line around pediatrics, respiratory Section, Cardiovascular Division, Department of Gastroenterology and other fields, the main products for the open throat sprays sword (childhood type), open throat sprays and strong sword Tianma Eucommia capsulesGuizhou three of the new board was listed in 2015, in June 2018 the new board delisted2020 April 28, Guizhou Sanli successfully listed on the Shanghai Stock ExchangeFriends of the three medical2019 years, the sales of medical expenses up to three friends 176 million yuan, accounting for the high and showed a substantial upward trendMost of the cost of sales is used for business serviceData show that the company's business service costs up to 135 million yuan in 2019, accounting for 76.48% of the proportion of the cost of sales data show that three friends of Medical was founded in April 2005, the main business of medical orthopedic implants supplies research and development, production and sales The company in 2020 April 9th ​​traded in Kechuang board The new pharmaceutical southern New South pharmaceutical sales in 2019 cost of 6.2149 billion yuan, accounting for 61.28% of revenue total revenue, cost of sales growth rate of 48.69 % The reason for the rapid growth of cost of sales, said the company mainly for the company to adapt to changes in the policy adjustment sales model, increase academic education and academic activities due to investment growth in 2019 due to the increase of cost of sales and wage increases of sales staff public information, the South is an innovative new pharmaceutical drug research and development as the core, the clinical demand, set drug research and development, production and sales in one of the innovative pharmaceutical companies 2020 March 26, the company in the Shanghai Stock Exchange Kechuang board officially listed Bio Integration annual report, Bio Integration cost of sales in 2019 of about 15,424,800 yuan In 118 stocks, Bio Integration cost of sales rate in 2019 of more than 2203.55%, ranked first place pharmaceutical companies public information, Bio Integration is mainly engaged in research and development of innovative drugs and bio-similar drugs, production operations, for the treatment of cancer, autoimmune diseases, cardiovascular diseases and other endanger human life or health Major diseases 2020 February 21, Bio Integration Branch at the Shanghai Stock Exchange board listed special treasure special treasure biological organisms 2019 cost of sales 4.1968 billion yuan, accounting for 57.51% of total revenue income According to a senior accountant said, "cost of sales is high relative to the normal of the pharmaceutical industry, but 60% is not a majority based on industry experience." explain this, especially given that biological treasure the company uses its own specialized team of academic promotion marketing model, the cost of sales personnel salaries and other fixed costs are relatively high The report shows that as of the end of 2019 Amoytop Biotech sales staff of 402 people Statistics show that special treasure is mainly engaged in biological and long-acting modified recombinant protein drug development, manufacture and marketing of innovative bio-pharmaceutical companies 2020 January 17, Special Biological Engineering Co., Ltd official visit Kechuang board.